PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTCT
Previous Symbol
CUSIPN/A
Phone908-222-7000
Debt
Debt-to-Equity Ratio0.55
Current Ratio4.34
Quick Ratio4.18
Price-To-Earnings
Trailing P/E Ratio-18.30
Forward P/E Ratio-33.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$194.39 million
Price / Sales9.56
Cash FlowN/A
Price / CashN/A
Book Value$3.77 per share
Price / Book9.81
Profitability
EPS (Most Recent Fiscal Year)($2.02)
Net Income$-79,000,000.00
Net Margins-25.03%
Return on Equity-27.41%
Return on Assets-11.96%
Miscellaneous
Employees373
Outstanding Shares50,260,000
Market Cap$1.91 billion
OptionableN/A
PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
How were PTC Therapeutics' earnings last quarter?
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.15. The biopharmaceutical company had revenue of $68.74 million for the quarter, compared to analyst estimates of $69.83 million. PTC Therapeutics had a negative return on equity of 27.41% and a negative net margin of 25.03%. View PTC Therapeutics' Earnings History.
When is PTC Therapeutics' next earnings date?
How can I listen to PTC Therapeutics' earnings call?
PTC Therapeutics will be holding an earnings conference call on Monday, November 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8773039216.
What price target have analysts set for PTCT?
9 brokerages have issued 12-month price targets for PTC Therapeutics' shares. Their predictions range from $11.00 to $66.00. On average, they expect PTC Therapeutics' share price to reach $43.8571 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for PTC Therapeutics.
What is the consensus analysts' recommendation for PTC Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PTC Therapeutics.
What are Wall Street analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
- 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (10/19/2018)
- 2. William Blair analysts commented, "We view this endpoint as particularly impressive given that this milestone is not reached in natural history and the Part II pivotal portion of FIREFISH is powered to show significant benefit if there are 5 sitters" out of a total of 40 infants. In addition, 90% of subjects were event-free at 10.5 months (compared with 50% in natural history) and median change in CHOP- INTEND total score from baseline was 16 at Day 245. While we acknowledge all the caveats associated with cross-trial comparison, we note that these data compare favorably with Spinraza’s Type 1 SMA study where 8% of patients achieved independent sitting and 10% achieved a rolling milestone. After speaking with management we believe that the FIREFISH Part II study enrollment should be completed by year-end, and the next clinical update could come at 2019 AAN." (10/3/2018)
- 3. Cowen Inc analysts commented, "Yesterday Clearside announced the completion of enrollment in the TYBEE study in." (10/25/2017)
Who are some of PTC Therapeutics' key competitors?
Some companies that are related to PTC Therapeutics include Beigene (BGNE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Amarin (AMRN), Dr.Reddy's Laboratories (RDY), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM) and Ligand Pharmaceuticals (LGND).
Who are PTC Therapeutics' key executives?
PTC Therapeutics' management team includes the folowing people:
- Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 58)
- Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 72)
- Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 40)
- Mr. Marcio Souza, Chief Operating Officer (Age 39)
- Dr. Neil Almstead, Exec. VP of Research, Pharmaceutical Operations & Technology (Age 51)
Who are PTC Therapeutics' major shareholders?
PTC Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Seven Eight Capital LP (0.13%), Strs Ohio (0.03%) and Lourd Capital LLC (0.01%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Dawn Svoronos, Marcio Souza, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.
Which institutional investors are buying PTC Therapeutics stock?
How do I buy shares of PTC Therapeutics?
Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PTC Therapeutics' stock price today?
One share of PTCT stock can currently be purchased for approximately $36.97.
How big of a company is PTC Therapeutics?
PTC Therapeutics has a market capitalization of $1.91 billion and generates $194.39 million in revenue each year. The biopharmaceutical company earns $-79,000,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. PTC Therapeutics employs 373 workers across the globe.
What is PTC Therapeutics' official website?
How can I contact PTC Therapeutics?
PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]
MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
